Laurent H Boissel

Title: Laurent H Boissel: A Renowned Innovator in the Field of Cancer Therapeutics

Introduction:

Laurent H Boissel is a prominent inventor and innovator based in Culver City, CA (US) with a remarkable portfolio of 20 patents. Known for his contributions in the field of cancer therapeutics, Boissel has made significant advancements in developing methods and compositions to combat myeloid-derived suppressor cells (MDSC) and tumor-associated macrophages (TAM). This article delves into Boissel's latest patents, career highlights, collaborations, and sheds light on his significant contributions to the industry.

Latest Patents:

Boissel's recent patents showcase his pioneering work in the field. One of the notable ones is the "Use of CD33CAR modified high affinity NK cells (t-haNK) to reduce myeloid-derived suppressor cell suppressor activity." This invention presents methods and compositions that effectively reduce the number of MDSC and TAM in a subject. By administering an antigen binding protein that targets CD33 expressed by MDSC and/or TAM, or using modified T cells or NK-92 cells expressing an antigen binding protein, Boissel's invention holds promise for treating diseases associated with MDSC and/or TAM infiltration into tissues or tumors.

Another noteworthy patent is for "Modified NK-92 haNK003 cells for the clinic." This patent introduces modified populations of NK-92 cells along with associated compositions, kits, and methods of manufacturing and utilizing these cells. These advancements open doors for innovative therapies and breakthroughs in cancer treatment.

Career Highlights:

Boissel has contributed significantly to various companies throughout his career. He has held positions at Nantkwest Inc. and Immunitybio, Inc., where his expertise in cancer research has been highly valued. Boissel's innovative mindset and commitment to advancing cancer therapeutics have made him a key figure within these organizations.

Collaborations:

Boissel's work has been complemented by collaborations with esteemed colleagues such as Hans G Klingemann and Barry J Simon. Through collaborative efforts, they have fostered invaluable advancements in the field of cancer therapeutics, solidifying Boissel's reputation as a respected and influential innovator.

Conclusion:

Laurent H Boissel's expertise and dedication in the field of cancer therapeutics have propelled him to the forefront of the industry. With an impressive portfolio of 20 patents, including groundbreaking inventions for reducing MDSC and TAM activity, he continues to make significant contributions to the field. Boissel's collaborations with esteemed colleagues further amplify his impact. As he continues to innovate and push boundaries, Laurent H Boissel remains a driving force in the quest for enhanced cancer treatments and improved patient outcomes.